{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:25:23Z","timestamp":1762176323266},"reference-count":39,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2009,1,21]],"date-time":"2009-01-21T00:00:00Z","timestamp":1232496000000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The optimal therapy for patients with the chronic hepatitis C virus (HCV) is a combination of peginterferon and ribavirin. Treating HCV without ribavirin or prematurely discontinuing, frequently missing doses of ribavirin is associated with a significant decline in virological response, and an increase in both breakthrough viraemia and relapse. The major limitation of ribavirin is adverse events, the most common of which is haemolytic anaemia. Haemolysis is modest when ribavirin is utilized as monotherapy, but is significantly increased when combined with interferon or peginterferon. For these reasons, attempts to replace ribavirin with a less toxic alternative have been advanced. Unfortunately, even when ribavirin is replaced by a potent protease inhibitor, relapse is significantly increased and SVR is reduced. The future of HCV treatment is to combine peginterferon and ribavirin with several protease and\/or polymerase inhibitors. Whether this strategy will allow ribavirin to be removed from the treatment paradigm remains to be proven. However, based on the results of clinical trials conducted to date, it is much more likely that peginterferon, not ribavirin, could be expendable.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2008.01936.x","type":"journal-article","created":{"date-parts":[[2009,1,21]],"date-time":"2009-01-21T13:54:10Z","timestamp":1232546050000},"page":"68-73","source":"Crossref","is-referenced-by-count":28,"title":["What future for ribavirin?"],"prefix":"10.1111","volume":"29","author":[{"given":"Mitchell L.","family":"Shiffman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,21]]},"reference":[{"key":"e_1_2_9_2_2","first-page":"1","article-title":"Ribavirin","volume":"2","author":"Fernandez H","year":"1986","journal-title":"a clinical overview"},{"key":"e_1_2_9_3_2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/135965350701200S03.1","article-title":"Respiratory syncytial virus infection in adults","volume":"12","author":"Murata Y","year":"2007","journal-title":"Antiviral Ther"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2005.06.027"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2.8.1317"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_9_8_2","first-page":"958","article-title":"Peginterferon\u2010alfa\u20102b plus ribavirin compared with interferon alfa\u20102b plus ribavirin for initial treatment of chronic hepatitis C","volume":"358","author":"Manns MP","year":"2001","journal-title":"a randomized trial"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.6.1139"},{"key":"e_1_2_9_10_2","first-page":"757","article-title":"The mechanism of action of ribavirin","volume":"14","author":"Cameron CE","year":"2001","journal-title":"lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/259496a0"},{"key":"e_1_2_9_12_2","first-page":"473","article-title":"Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C","volume":"26","author":"Bodenheimer HC","year":"1997","journal-title":"a multicenter trial"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50218"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.04.009"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.07.022"},{"key":"e_1_2_9_16_2","first-page":"346","article-title":"Peginterferon\u2010alfa 2a and ribavirin combination therapy in chronic hepatitis C","volume":"140","author":"Hadziyannis SJ","year":"2004","journal-title":"a randomized study of treatment duration and ribavirin dose"},{"key":"e_1_2_9_17_2","first-page":"971","article-title":"Peginterferon alfa\u20102b and weight\u2010based or flat\u2010dose ribavirin in chronic hepatitis C patients","volume":"46","author":"Jacobson IM","year":"2007","journal-title":"a randomized trial"},{"key":"e_1_2_9_18_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1665-2681(19)32118-0","article-title":"Side effects of medical therapy for chronic hepatitis C","volume":"3","author":"Shiffman ML.","year":"2004","journal-title":"Ann Hepatol"},{"issue":"1","key":"e_1_2_9_19_2","first-page":"17","article-title":"The clinical pharmacology of ribavirin","volume":"19","author":"Glue P.","year":"1999","journal-title":"Semin Liver Dis"},{"key":"e_1_2_9_20_2","first-page":"997","article-title":"Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection","volume":"31","author":"De Franceschi L","year":"2000","journal-title":"role of membrane oxidative damage"},{"issue":"1","key":"e_1_2_9_21_2","first-page":"67","article-title":"Safety of combination interferon alfa\u20102b\/ribavirin therapy in chronic hepatitis C\u2010relapsed and treatment\u2010naive patients","volume":"19","author":"Maddrey WC.","year":"1999","journal-title":"Semin Liver Dis"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01139.x"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.35950"},{"key":"e_1_2_9_24_2","first-page":"487","article-title":"Optimizing the current therapy for chronic hepatitis C virus","volume":"12","author":"Shiffman ML.","year":"2008","journal-title":"peginterferon and ribavirin dosing and the utility of growth factors"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.011"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.10.008"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20482"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21409"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21712"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2006.00749.x"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066403"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632020601700105"},{"issue":"2","key":"e_1_2_9_33_2","first-page":"39","article-title":"Virologic response and safety outcomes in therapy\u2010na\u00efve patients treated for chronic hepatitis C with viramadine in combination with pegylated interferon alfa\u20102a","volume":"42","author":"Gish R","year":"2005","journal-title":"J Hepatol"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(06)80739-7"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22357"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.03.027"},{"issue":"2","key":"e_1_2_9_37_2","first-page":"S4","article-title":"Prove 1","volume":"48","author":"Mchutchison JG","year":"2008","journal-title":"results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-na\u00efve subjects with hepatitis C"},{"issue":"2","key":"e_1_2_9_38_2","first-page":"S26","article-title":"Treatment of chronic hepatitis C with telaprevir in combination with peginterferon alfa\u20102a with or without ribavirin","volume":"48","author":"Dusheiko GM","year":"2008","journal-title":"further interim analysis results of the prove 2 study"},{"issue":"2","key":"e_1_2_9_39_2","first-page":"S372","article-title":"Interm results from HCV sprint\u20101","volume":"48","author":"Kwo P","year":"2008","journal-title":"RVR\/EVR from phase 2 study of boceprevir plus pegintron (peginterferon alfa-2b)\/ribavirin in treatment na\u00efve subjects with genotype-1 CHC"},{"key":"e_1_2_9_40_2","first-page":"431A","article-title":"A phase 2b study of telaprevir with peginterferon alfa\u20102a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon alfa\u20102a\/b and ribavirin therapy. Prove 3 interim results","volume":"48","author":"McHutchison JG","year":"2008","journal-title":"Hepatology"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2008.01936.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2008.01936.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T15:03:53Z","timestamp":1694444633000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2008.01936.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":39,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1111\/j.1478-3231.2008.01936.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2008.01936.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}